RE: BC 20120 Nov 2020 08:14
agree Minnissage
ice9
@__ice9
Missed this earlier, but TMPRSS4 is also a viable viral entry route for SARS-CoV-2.
This adds to TMPRSS2/13/11.
Any of the broad-spectrum serine protease inhibitors should still work on it, though.
The small intestine contains huge amounts of convenient ACE2 and TMPRSS2.
TMPRSS2 is still the main entry route in the lungs specifically, though 13 and 11 also matter in the lungs and respiratory tract in general.
Circumstantial evidence suggests they may in the nasal passages as well.
Nebulized aprotinin does so directly.
Bromhexine/ambroxol indirectly inhibit the various TMPRSS isoforms in the lungs.
And actually it appears TMPRSS4 (also present) is amenable to use as well.Camostat/nafamostat do so directly, systemically.
Spironolactone, dutasteride, SSRIs to a more limited extent, and in general anti-androgens are all more specific to TMPRSS2, however.
Lungs are known for rather large surface area as well, given they also handle interfacial chemical exchange
4 months after acute recovery, there are still signs of persistent viral replication in the GI tract in some former COVID-19 patients.
Interesting development.
https://twitter.com/__ice9/status/1329608683651817475